

<b>NCT ID</b>	NCT02886585
<b>Title</b>	Pembrolizumab In Central Nervous System Metastases
<b>Phase</b>	Phase 2
<b>Date Added</b>	2016-09-01
<b>Location</b>	Massachusetts, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Pembrolizumab
<b>Tags</b>	MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT03030378
<b>Title</b>	Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
<b>Phase</b>	Phase 1
<b>Date Added</b>	2017-01-25
<b>Location</b>	California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Iowa, United States Maryland, United States Massachusetts, United States Missouri, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States Texas, United States Virginia, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Edodekin alfa, Pembrolizumab
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT05201612
<b>Title</b>	Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).
<b>Phase</b>	Phase 2
<b>Date Added</b>	2022-01-21
<b>Location</b>	Spain
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Unknown status
<b>Drugs</b>	Olaparib, Pembrolizumab
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT05333809
<b>Title</b>	Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer
<b>Phase</b>	Phase 2
<b>Date Added</b>	2022-04-19
<b>Location</b>	
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes

<b>Status</b>	Not yet recruiting
<b>Drugs</b>	Disitamab vedotin, Pembrolizumab, Keytruda
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT05491083
<b>Title</b>	Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2022-08-08
<b>Location</b>	Singapore
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	No
<b>Status</b>	Recruiting
<b>Drugs</b>	Pembrolizumab & ADG106 (Phase Ib), Pembrolizumab & ADG106 (Phase II)
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT03844750
<b>Title</b>	Pembrolizumab After Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Who Are Undergoing Liver Surgery
<b>Phase</b>	Phase 2
<b>Date Added</b>	2019-02-18
<b>Location</b>	California, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Pembrolizumab, Vactosertib, Keytruda
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT03239145
<b>Title</b>	Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
<b>Phase</b>	Phase 1
<b>Date Added</b>	2017-08-03
<b>Location</b>	Massachusetts, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Completed
<b>Drugs</b>	Pembrolizumab, Trebananib
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT03638297
<b>Title</b>	PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer
<b>Phase</b>	Phase 2
<b>Date Added</b>	2018-08-20
<b>Location</b>	China
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	PD-1 antibody + cox inhibitor
<b>Tags</b>	MSI-H/ MMRd
<b>NCT ID</b>	NCT02215889
<b>Title</b>	Partial Liver Segment 2/3 Transplantation Study

Phase	Phase 1
Date Added	2014-08-13
Location	Norway
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp

---

NCT ID	NCT06764680
Title	Oral Chemotherapy, Targeted Therapy and Immunotherapy With/without Radiotherapy As 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer
Phase	Phase 2
Date Added	2025-01-08
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSS/ MMRp